Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax Gets Aggressive With Its Respiratory Syncytial Virus Vaccine

This article was originally published in Scrip

Executive Summary

The prospect of a prophylactic vaccine against respiratory syncytial virus (RSV) has come a step closer with the lead product candidate, Novovax Inc.'s RSV F Vaccine, meeting its major endpoints in a Phase II trial in older adults.

You may also be interested in...



Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails

Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?

Case Studies: How Three Public Companies Financed R&D In A Tough Market

The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029474

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel